2021 Q4 Form 10-K Financial Statement
#000147793222002079 Filed on April 06, 2022
Income Statement
| Concept | 2021 Q4 | 2021 | 2020 Q4 |
|---|---|---|---|
| Revenue | $0.00 | $50.00K | $0.00 |
| YoY Change | 0.0% | -100.0% | |
| Cost Of Revenue | |||
| YoY Change | |||
| Gross Profit | |||
| YoY Change | |||
| Gross Profit Margin | |||
| Selling, General & Admin | $162.0K | $727.0K | $173.0K |
| YoY Change | -6.36% | 1.82% | 2.37% |
| % of Gross Profit | |||
| Research & Development | $2.000K | $10.00K | $0.00 |
| YoY Change | -9.09% | -100.0% | |
| % of Gross Profit | |||
| Depreciation & Amortization | $1.000K | $2.000K | $0.00 |
| YoY Change | 0.0% | -100.0% | |
| % of Gross Profit | |||
| Operating Expenses | $164.0K | $10.00K | $176.0K |
| YoY Change | -6.82% | -9.09% | 2.92% |
| Operating Profit | -$687.0K | ||
| YoY Change | 1.78% | ||
| Interest Expense | $130.0K | $26.00K | $2.933M |
| YoY Change | -95.57% | 4.0% | -405.2% |
| % of Operating Profit | |||
| Other Income/Expense, Net | -$2.952M | ||
| YoY Change | -159.17% | ||
| Pretax Income | -$34.00K | -$3.639M | $2.757M |
| YoY Change | -101.23% | -184.35% | -349.05% |
| Income Tax | $0.00 | ||
| % Of Pretax Income | |||
| Net Earnings | -$34.00K | -$3.639M | $2.757M |
| YoY Change | -101.23% | -184.35% | -349.05% |
| Net Earnings / Revenue | -7278.0% | ||
| Basic Earnings Per Share | -$0.01 | ||
| Diluted Earnings Per Share | -$60.79 | -$0.01 | $4.720K |
| COMMON SHARES | |||
| Basic Shares Outstanding | 559.3M shares | 559.3M shares | |
| Diluted Shares Outstanding | 559.3M shares |
Balance Sheet
| Concept | 2021 Q4 | 2021 | 2020 Q4 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $232.0K | $232.0K | $353.0K |
| YoY Change | -34.28% | -34.28% | 35.25% |
| Cash & Equivalents | $232.0K | $353.0K | |
| Short-Term Investments | |||
| Other Short-Term Assets | $15.00K | $15.00K | $12.00K |
| YoY Change | 25.0% | 25.0% | -7.69% |
| Inventory | |||
| Prepaid Expenses | $15.00K | $12.00K | |
| Receivables | |||
| Other Receivables | |||
| Total Short-Term Assets | $547.0K | $547.0K | $665.0K |
| YoY Change | -17.74% | -17.74% | 15.85% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $4.000K | $4.000K | $6.000K |
| YoY Change | -33.33% | -33.33% | 50.0% |
| Goodwill | |||
| YoY Change | |||
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | $2.901M | $2.901M | $5.875M |
| YoY Change | -50.62% | -50.62% | 462.2% |
| Other Assets | $2.000K | $2.000K | $2.000K |
| YoY Change | 0.0% | 0.0% | 0.0% |
| Total Long-Term Assets | $2.907M | $2.907M | $6.183M |
| YoY Change | -52.98% | -52.98% | 274.5% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $547.0K | $547.0K | $665.0K |
| Total Long-Term Assets | $2.907M | $2.907M | $6.183M |
| Total Assets | $3.454M | $3.454M | $6.848M |
| YoY Change | -49.56% | -49.56% | 207.78% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $102.0K | $102.0K | $160.0K |
| YoY Change | -36.25% | -35.85% | -31.62% |
| Accrued Expenses | $1.129M | $1.129M | $853.0K |
| YoY Change | 32.36% | 32.36% | -54.14% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $130.0K | $130.0K | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | |||
| YoY Change | |||
| Total Short-Term Liabilities | $1.361M | $1.361M | $1.012M |
| YoY Change | 34.49% | 34.49% | -51.67% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $0.00 | $0.00 | $104.0K |
| YoY Change | -100.0% | -100.0% | 33.33% |
| Other Long-Term Liabilities | |||
| YoY Change | |||
| Total Long-Term Liabilities | $0.00 | $0.00 | $104.0K |
| YoY Change | -100.0% | -100.0% | 33.33% |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $1.361M | $1.361M | $1.012M |
| Total Long-Term Liabilities | $0.00 | $0.00 | $104.0K |
| Total Liabilities | $1.361M | $1.361M | $1.116M |
| YoY Change | 21.95% | 21.95% | -48.62% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$68.52M | -$64.88M | |
| YoY Change | 5.61% | ||
| Common Stock | $559.0K | $559.0K | |
| YoY Change | 0.0% | ||
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $1.035M | $2.093M | $4.674M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $3.454M | $3.454M | $6.848M |
| YoY Change | -49.56% | -49.56% | 207.78% |
Cashflow Statement
| Concept | 2021 Q4 | 2021 | 2020 Q4 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$34.00K | -$3.639M | $2.757M |
| YoY Change | -101.23% | -184.35% | -349.05% |
| Depreciation, Depletion And Amortization | $1.000K | $2.000K | $0.00 |
| YoY Change | 0.0% | -100.0% | |
| Cash From Operating Activities | -$134.0K | -$421.0K | -$121.0K |
| YoY Change | 10.74% | 8.51% | 65.75% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | $0.00 | $0.00 | $0.00 |
| YoY Change | -100.0% | ||
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | $0.00 | $300.0K | $0.00 |
| YoY Change | -38.02% | -100.0% | |
| Cash From Investing Activities | $0.00 | $300.0K | $0.00 |
| YoY Change | -37.5% | -100.0% | |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | |||
| YoY Change | |||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | 0.000 | $0.00 | 0.000 |
| YoY Change | -100.0% | ||
| NET CHANGE | |||
| Cash From Operating Activities | -134.0K | -$421.0K | -121.0K |
| Cash From Investing Activities | 0.000 | $300.0K | 0.000 |
| Cash From Financing Activities | 0.000 | $0.00 | 0.000 |
| Net Change In Cash | -134.0K | -$121.0K | -121.0K |
| YoY Change | 10.74% | -231.52% | -203.42% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$134.0K | -$421.0K | -$121.0K |
| Capital Expenditures | $0.00 | $0.00 | $0.00 |
| Free Cash Flow | -$134.0K | -$421.0K | -$121.0K |
| YoY Change | 10.74% | 7.4% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2021 | dei |
Auditor Location
AuditorLocation
|
Draper, UT | |
| CY2021Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
232000 | USD |
| CY2020Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
353000 | USD |
| CY2021Q4 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
15000 | USD |
| CY2020Q4 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
12000 | USD |
| CY2021Q4 | us-gaap |
Due From Related Parties Current
DueFromRelatedPartiesCurrent
|
300000 | USD |
| CY2020Q4 | us-gaap |
Due From Related Parties Current
DueFromRelatedPartiesCurrent
|
300000 | USD |
| CY2021Q4 | us-gaap |
Assets Current
AssetsCurrent
|
547000 | USD |
| CY2020Q4 | us-gaap |
Assets Current
AssetsCurrent
|
665000 | USD |
| CY2021Q4 | us-gaap |
Investments
Investments
|
2901000 | USD |
| CY2020Q4 | us-gaap |
Investments
Investments
|
5875000 | USD |
| CY2021Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
4000 | USD |
| CY2020Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
6000 | USD |
| CY2021Q4 | us-gaap |
Due From Related Parties Noncurrent
DueFromRelatedPartiesNoncurrent
|
0 | USD |
| CY2020Q4 | us-gaap |
Due From Related Parties Noncurrent
DueFromRelatedPartiesNoncurrent
|
300000 | USD |
| CY2021Q4 | us-gaap |
Other Assets
OtherAssets
|
2000 | USD |
| CY2020Q4 | us-gaap |
Other Assets
OtherAssets
|
2000 | USD |
| CY2021Q4 | us-gaap |
Assets
Assets
|
3454000 | USD |
| CY2020Q4 | us-gaap |
Assets
Assets
|
6848000 | USD |
| CY2021Q4 | us-gaap |
Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
|
102000 | USD |
| CY2020Q4 | us-gaap |
Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
|
159000 | USD |
| CY2021Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
1129000 | USD |
| CY2020Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
853000 | USD |
| CY2021Q4 | us-gaap |
Notes Payable
NotesPayable
|
130000 | USD |
| CY2020Q4 | us-gaap |
Notes Payable
NotesPayable
|
0 | USD |
| CY2021Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
1361000 | USD |
| CY2020Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
1012000 | USD |
| CY2021Q4 | us-gaap |
Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
|
0 | USD |
| CY2020Q4 | us-gaap |
Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
|
104000 | USD |
| CY2021Q4 | us-gaap |
Liabilities Noncurrent
LiabilitiesNoncurrent
|
0 | USD |
| CY2020Q4 | us-gaap |
Liabilities Noncurrent
LiabilitiesNoncurrent
|
104000 | USD |
| CY2021Q4 | us-gaap |
Liabilities
Liabilities
|
1361000 | USD |
| CY2020Q4 | us-gaap |
Liabilities
Liabilities
|
1116000 | USD |
| CY2021Q4 | us-gaap |
Redeemable Noncontrolling Interest Equity Preferred Carrying Amount
RedeemableNoncontrollingInterestEquityPreferredCarryingAmount
|
1058000 | USD |
| CY2020Q4 | us-gaap |
Redeemable Noncontrolling Interest Equity Preferred Carrying Amount
RedeemableNoncontrollingInterestEquityPreferredCarryingAmount
|
1058000 | USD |
| CY2020Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2020Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
1000000 | shares |
| CY2021Q4 | mhtx |
Preferred Stock Undesignated Shares
PreferredStockUndesignatedShares
|
447804 | shares |
| CY2021Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
| CY2020Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
| CY2021Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | USD |
| CY2020Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | USD |
| CY2020Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
950000000 | shares |
| CY2021Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
559281064 | shares |
| CY2020Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
559281064 | shares |
| CY2021Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
559000 | USD |
| CY2020Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
559000 | USD |
| CY2021Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
68996000 | USD |
| CY2020Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
68996000 | USD |
| CY2021Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-68520000 | USD |
| CY2020Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-64881000 | USD |
| CY2021Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
1035000 | USD |
| CY2020Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
4674000 | USD |
| CY2021Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
3454000 | USD |
| CY2020Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
6848000 | USD |
| CY2021 | us-gaap |
Revenues
Revenues
|
50000 | USD |
| CY2020 | us-gaap |
Revenues
Revenues
|
50000 | USD |
| CY2021 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
727000 | USD |
| CY2020 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
714000 | USD |
| CY2021 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
10000 | USD |
| CY2020 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
11000 | USD |
| CY2021 | us-gaap |
Operating Costs And Expenses
OperatingCostsAndExpenses
|
737000 | USD |
| CY2020 | us-gaap |
Operating Costs And Expenses
OperatingCostsAndExpenses
|
725000 | USD |
| CY2021 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-687000 | USD |
| CY2020 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-675000 | USD |
| CY2021 | mhtx |
Gain On Sale Of Investment
GainOnSaleOfInvestment
|
-2974000 | USD |
| CY2020 | mhtx |
Gain On Sale Of Investment
GainOnSaleOfInvestment
|
5014000 | USD |
| CY2021 | us-gaap |
Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
|
48000 | USD |
| CY2020 | us-gaap |
Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
|
0 | USD |
| CY2021 | us-gaap |
Interest Expense
InterestExpense
|
26000 | USD |
| CY2021Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
1035000 | USD |
| CY2021 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.01 | |
| CY2020 | us-gaap |
Interest Expense
InterestExpense
|
25000 | USD |
| CY2021 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-2952000 | USD |
| CY2020 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
4989000 | USD |
| CY2021 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-3639000 | USD |
| CY2020 | us-gaap |
Net Income Loss
NetIncomeLoss
|
4314000 | USD |
| CY2021 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.01 | |
| CY2020 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.01 | |
| CY2021 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
559281064 | shares |
| CY2020 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
593051310 | shares |
| CY2021 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.01 | |
| CY2020 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.01 | |
| CY2019Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-1005000 | USD |
| CY2020 | us-gaap |
Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax
|
1341000 | USD |
| CY2020 | us-gaap |
Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
|
24000 | USD |
| CY2020 | us-gaap |
Net Income Loss
NetIncomeLoss
|
4314000 | USD |
| CY2020Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
4674000 | USD |
| CY2021 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-3639000 | USD |
| CY2021 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-3639000 | USD |
| CY2020 | us-gaap |
Net Income Loss
NetIncomeLoss
|
4314000 | USD |
| CY2021 | mhtx |
Common Stock Issued For Services
CommonStockIssuedForServices
|
0 | USD |
| CY2020 | mhtx |
Common Stock Issued For Services
CommonStockIssuedForServices
|
24000 | USD |
| CY2021 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
2000 | USD |
| CY2020 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
2000 | USD |
| CY2021 | mhtx |
Loss Gain On Fair Value Adjustment Of Investments
LossGainOnFairValueAdjustmentOfInvestments
|
-2974000 | USD |
| CY2020 | mhtx |
Loss Gain On Fair Value Adjustment Of Investments
LossGainOnFairValueAdjustmentOfInvestments
|
5014000 | USD |
| CY2021 | mhtx |
Gain Loss Related To Litigation Settlements
GainLossRelatedToLitigationSettlements
|
-48000 | USD |
| CY2020 | mhtx |
Gain Loss Related To Litigation Settlements
GainLossRelatedToLitigationSettlements
|
0 | USD |
| CY2021 | us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
26000 | USD |
| CY2020 | us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
26000 | USD |
| CY2020 | us-gaap |
Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
|
-1000 | USD |
| CY2021 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-105000 | USD |
| CY2020 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-10250 | USD |
| CY2021 | us-gaap |
Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
|
276000 | USD |
| CY2020 | us-gaap |
Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
|
269250 | USD |
| CY2021 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-421000 | USD |
| CY2020 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-388000 | USD |
| CY2021 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
0 | USD |
| CY2020 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
4000 | USD |
| CY2021 | us-gaap |
Proceeds From Sale Of Property Held For Sale
ProceedsFromSaleOfPropertyHeldForSale
|
300000 | USD |
| CY2020 | us-gaap |
Proceeds From Sale Of Property Held For Sale
ProceedsFromSaleOfPropertyHeldForSale
|
300000 | USD |
| CY2021 | us-gaap |
Proceeds From Sale Of Investment Projects
ProceedsFromSaleOfInvestmentProjects
|
0 | USD |
| CY2020 | us-gaap |
Proceeds From Sale Of Investment Projects
ProceedsFromSaleOfInvestmentProjects
|
184000 | USD |
| CY2021 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
300000 | USD |
| CY2020 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
480000 | USD |
| CY2021 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
0 | USD |
| CY2020 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
0 | USD |
| CY2021 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
|
-121000 | USD |
| CY2020 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
|
92000 | USD |
| CY2020Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
353000 | USD |
| CY2019Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
261000 | USD |
| CY2021Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
232000 | USD |
| CY2020Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
353000 | USD |
| CY2021 | us-gaap |
Interest Paid
InterestPaid
|
0 | USD |
| CY2020 | us-gaap |
Interest Paid
InterestPaid
|
0 | USD |
| CY2021 | us-gaap |
Income Taxes Paid
IncomeTaxesPaid
|
0 | USD |
| CY2020 | us-gaap |
Income Taxes Paid
IncomeTaxesPaid
|
0 | USD |
| CY2021 | mhtx |
Reclassification Of Liabilities To Equity
ReclassificationOfLiabilitiesToEquity
|
0 | USD |
| CY2020 | mhtx |
Reclassification Of Liabilities To Equity
ReclassificationOfLiabilitiesToEquity
|
1341000 | USD |
| CY2021Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-68520000 | USD |
| CY2021Q4 | mhtx |
Working Capital
WorkingCapital
|
684000 | USD |
| CY2021 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">USE OF ESTIMATES:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amount of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. A significant estimate includes the carrying value of the Company’s patents, fair value of the Company’s common stock, assumptions used in calculating the value of stock options, depreciation and amortization.</p> | |
| CY2021 | mhtx |
Cash Concentration
CashConcentration
|
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CASH CONCENTRATION:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company’s cash accounts are federally insured up to $250,000 for each financial institution we hold our accounts in. As of December 31, 2021 and December 31, 2020, we had cash balances of $-0- and $103,000 exceeding the federally insured limits.</p> | |
| CY2021Q4 | us-gaap |
Cash Fdic Insured Amount
CashFDICInsuredAmount
|
250000 | USD |
| CY2021 | us-gaap |
Federal Deposit Insurance Corporation Premium Expense
FederalDepositInsuranceCorporationPremiumExpense
|
0 | USD |
| CY2020 | us-gaap |
Federal Deposit Insurance Corporation Premium Expense
FederalDepositInsuranceCorporationPremiumExpense
|
103000 | USD |
| CY2018 | mhtx |
Adjusted Asset Valuation
AdjustedAssetValuation
|
1200000 | USD |
| CY2019 | mhtx |
Sale Of Asset
SaleOfAsset
|
1200000 | USD |
| CY2019 | us-gaap |
Proceeds From Sale Of Property Held For Sale
ProceedsFromSaleOfPropertyHeldForSale
|
300000 | USD |
| CY2019Q4 | mhtx |
Remaining Amount Of Assets
RemainingAmountOfAssets
|
900000 | USD |
| CY2020Q2 | us-gaap |
Proceeds From Sale Of Property Held For Sale
ProceedsFromSaleOfPropertyHeldForSale
|
300000 | USD |
| CY2021 | mhtx |
Common Stock Owned Share
CommonStockOwnedShare
|
52516508 | shares |
| CY2020Q4 | us-gaap |
Investments
Investments
|
5875000 | USD |
| CY2021 | us-gaap |
Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
|
559281064 | shares |
| CY2020 | us-gaap |
Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
|
593051310 | shares |
| CY2021 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.01 | |
| CY2021 | us-gaap |
Pro Forma Weighted Average Shares Outstanding Diluted
ProFormaWeightedAverageSharesOutstandingDiluted
|
26655760 | shares |
| CY2020 | us-gaap |
Pro Forma Weighted Average Shares Outstanding Diluted
ProFormaWeightedAverageSharesOutstandingDiluted
|
33655760 | shares |
| CY2021 | us-gaap |
Profit Loss
ProfitLoss
|
-3639000 | USD |
| CY2020 | us-gaap |
Profit Loss
ProfitLoss
|
4314000 | USD |
| CY2021 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
559281064 | shares |
| CY2020 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
558322048 | shares |
| CY2020 | mhtx |
Effect Of Dilutive Securities
EffectOfDilutiveSecurities
|
34729262 | shares |
| CY2021 | mhtx |
Begining Balance
BeginingBalance
|
5875000 | USD |
| CY2021 | mhtx |
Change In The Unrealized Fair Value Of Securities
ChangeInTheUnrealizedFairValueOfSecurities
|
-2974000 | USD |
| CY2021 | mhtx |
Ending Balance
EndingBalance
|
2901000 | USD |
| CY2021 | mhtx |
Schedule Of Debt Discount
ScheduleOfDebtDiscount
|
<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Notes payable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">150,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Less: Discounts on notes payable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(20,000 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Notes payable, net of discounts</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">130,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table> | |
| CY2021Q4 | us-gaap |
Notes Payable Current
NotesPayableCurrent
|
150000 | USD |
| CY2021Q4 | mhtx |
Less Discounts On Notes Payable
LessDiscountsOnNotesPayable
|
-20000 | USD |
| CY2021Q4 | us-gaap |
Notes Payable
NotesPayable
|
130000 | USD |
| CY2021Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
1000000 | shares |
| CY2021Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
950000000 | shares |
| CY2021Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
559281064 | shares |
| CY2021Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
559281064 | shares |
| CY2021 | mhtx |
Reclassification Of Liability
ReclassificationOfLiability
|
1341000 | USD |
| CY2021Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
26500000 | shares |
| CY2021Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
1595000 | USD |
| CY2020 | mhtx |
Number Of Options Outstanding Beginning Balance
NumberOfOptionsOutstandingBeginningBalance
|
22075000 | shares |
| CY2021 | mhtx |
Weighted Average Exercise Price Beginning
WeightedAverageExercisePriceBeginning
|
0.07 | |
| CY2020 | mhtx |
Weighted Average Life Outstanding Beginning Balance
WeightedAverageLifeOutstandingBeginningBalance
|
P3Y2M12D | |
| CY2020 | mhtx |
Number Of Options Exercisable Outstanding Beginning Balance
NumberOfOptionsExercisableOutstandingBeginningBalance
|
22075000 | shares |
| CY2020 | mhtx |
Aggregate Intrinsic Value Beginning
AggregateIntrinsicValueBeginning
|
0 | USD |
| CY2020 | mhtx |
Aggregate Intrinsic Value Outstanding
AggregateIntrinsicValueOutstanding
|
0 | USD |
| CY2020 | mhtx |
Aggregate Intrinsic Value Granted
AggregateIntrinsicValueGranted
|
0 | USD |
| CY2020 | mhtx |
Share Based Compensation Arrangement By Share Based Payment Award Options Expiration In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationInPeriod
|
-3575000 | shares |
| CY2021 | mhtx |
Weighted Average Exercise Price Expired
WeightedAverageExercisePriceExpired
|
0.07 | |
| CY2020 | mhtx |
Share Based Compensation Arrangement By Share Based Payment Award Options Expired Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredExercisableNumber
|
-3575000 | shares |
| CY2021 | mhtx |
Number Of Options Outstanding Beginning Balance
NumberOfOptionsOutstandingBeginningBalance
|
18500000 | shares |
| CY2020 | mhtx |
Weighted Average Exercise Price Beginning
WeightedAverageExercisePriceBeginning
|
0.07 | |
| CY2021 | mhtx |
Weighted Average Life Outstanding Beginning Balance
WeightedAverageLifeOutstandingBeginningBalance
|
P2Y10M2D | |
| CY2021 | mhtx |
Number Of Options Exercisable Outstanding Beginning Balance
NumberOfOptionsExercisableOutstandingBeginningBalance
|
18500000 | shares |
| CY2021 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
15000000 | shares |
| CY2021 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
0.02 | |
| CY2021 | mhtx |
Weighted Average Life Granted
WeightedAverageLifeGranted
|
P9Y8M4D | |
| CY2021 | mhtx |
Share Based Compensation Arrangement By Share Based Payment Award Options Granted Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedExercisableNumber
|
15000000 | shares |
| CY2021 | mhtx |
Aggregate Intrinsic Value Beginning
AggregateIntrinsicValueBeginning
|
15500 | USD |
| CY2021 | mhtx |
Share Based Compensation Arrangement By Share Based Payment Award Options Expiration In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationInPeriod
|
-7000000 | shares |
| CY2020 | mhtx |
Weighted Average Exercise Price Expired
WeightedAverageExercisePriceExpired
|
0.07 | |
| CY2021 | mhtx |
Share Based Compensation Arrangement By Share Based Payment Award Options Expired Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredExercisableNumber
|
-7000000 | shares |
| CY2021 | mhtx |
Number Of Options Outstanding Ending Balance
NumberOfOptionsOutstandingEndingBalance
|
26500000 | shares |
| CY2021 | mhtx |
Weighted Average Exercise Price Outstanding Ending Balance
WeightedAverageExercisePriceOutstandingEndingBalance
|
0.04 | |
| CY2021 | mhtx |
Weighted Average Life Outstanding Ending Balance
WeightedAverageLifeOutstandingEndingBalance
|
P6Y21D | |
| CY2021 | mhtx |
Number Of Options Exercisable Outstanding Ending Balance
NumberOfOptionsExercisableOutstandingEndingBalance
|
26500000 | shares |
| CY2021 | mhtx |
Aggregate Intrinsic Value Outstanding
AggregateIntrinsicValueOutstanding
|
15000 | USD |
| CY2021 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | USD |
| CY2020 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | USD |
| CY2021Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
12704000 | USD |
| CY2020Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
12630000 | USD |
| CY2021Q4 | us-gaap |
Deferred Tax Assets Other
DeferredTaxAssetsOther
|
6988000 | USD |
| CY2020Q4 | us-gaap |
Deferred Tax Assets Other
DeferredTaxAssetsOther
|
6988000 | USD |
| CY2021Q4 | mhtx |
Less Valuation Allowance
LessValuationAllowance
|
-19692000 | USD |
| CY2020Q4 | mhtx |
Less Valuation Allowance
LessValuationAllowance
|
-19618000 | USD |
| CY2021Q4 | us-gaap |
Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
|
0 | USD |
| CY2020Q4 | us-gaap |
Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
|
0 | USD |
| CY2021Q4 | us-gaap |
Operating Loss Carryforwards
OperatingLossCarryforwards
|
47275000 | USD |
| CY2020Q4 | us-gaap |
Operating Loss Carryforwards
OperatingLossCarryforwards
|
47043000 | USD |
| CY2021 | mhtx |
Federal Tax Purposes Expire
FederalTaxPurposesExpire
|
through 2031 | |
| CY2021 | mhtx |
State Tax Purposes Expire
StateTaxPurposesExpire
|
through 2025 | |
| CY2021 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.21 | pure |
| CY2021 | mhtx |
Tax Benefit Computed At21
TaxBenefitComputedAt21
|
0 | USD |
| CY2020 | mhtx |
Tax Benefit Computed At21
TaxBenefitComputedAt21
|
0 | USD |
| CY2020 | us-gaap |
Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
0 | USD |
| CY2021 | us-gaap |
Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
0 | USD |
| CY2021 | mhtx |
Change In Carryovers And Tax Attributes
ChangeInCarryoversAndTaxAttributes
|
0 | USD |
| CY2021 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | USD |
| CY2020 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | USD |
| CY2021 | mhtx |
Royalty Percentage On Dental Products
RoyaltyPercentageOnDentalProducts
|
0.10 | pure |
| CY2021 | mhtx |
Royalty Percentage On Other Licensed Products
RoyaltyPercentageOnOtherLicensedProducts
|
0.05 | pure |
| CY2021 | us-gaap |
Royalty Expense
RoyaltyExpense
|
50000 | USD |
| CY2020 | us-gaap |
Royalty Expense
RoyaltyExpense
|
50000 | USD |
| CY2021Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
1129000 | USD |
| CY2020Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
853000 | USD |
